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avoided versus ENOX’ was quantiﬁed using a modelling
approach based on decision-tree technique synthesising pub-
lished data and a hospital survey. Safety and efﬁcacy values of
VTE prevention with the comparators were taken from the
EPHESUS [Lassen et al. Lancet 2002], PENTAMAKS [Bauer
et al. NEJM 2001] and PENTHIFRA [Eriksson et al. NEJM
2001] trials. Data on resource utilization (staff, drugs, materials,
laboratory, and equipment) during thromboprophylaxis, diagno-
sis and treatment came from the hospital survey. Resources were
valued in internal hospital prices as of the ﬁrst quarter of 2007.
The evaluation exclusively encompassed inpatient days for
thromboprophylaxis and treatment of VTE and major bleed
during the MOSLL-related hospital stay. RESULTS: In the base-
case analysis, FOND dominated ENOX: cost savings of €3430
were obtained and 11.8 clinical VTE were avoided by FOND
versus ENOX, each per 1000 patients. In comprehensive sensi-
tivity analyses, using impact analysis and Monte Carlo simula-
tion, the robustness of these results was tested. The rate of
prophylaxis-related bleeding with FOND (RPBF) had the great-
est impact on the savings. FOND remained cost-saving in 61%
and 77% of 10,000 iterations with the ﬁrst FOND injection 6
hours after surgical closure (RPBF = 0.028) or the morning after
surgery (RPBF = 0.019), respectively. FOND remained more
effective than ENOX without exception: after 10,000 iterations,
between 4.6 and 21.2 clinical VTE were avoided by FOND
versus ENOX per 1000 patients. CONCLUSION: FOND offers
hospitals in Germany a clinically and economically advantageous
alternative for prevention and treatment of VTE in patients
undergoing MOSLL.
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OBJECTIVES: To evaluate the long-term outcomes of serolimus-
eluting stents (SES) in comparison to bare-metal stents (BMS)
in elective treatment of coronary artery disease (CAD).
METHODS: In the prospectiveGERSHWIN study in 35 hospitals
in Germany, CAD patients undergoing percutaneous coronary
intervention (PCI) were electively treated with SES or BMS
(sequential control design with a case : control ratio of 2 : 1).
Standardized questionnaires completed by patients and physicians
at 3, 6, 12, and 18 months following PCI documented major
adverse coronary events (MACE), including death, myocardial
infarct, coronary bypass surgery and re-PCI in target vessel (TVR),
as well as disease-related direct and indirect costs. RESULTS:
From April 2003 until June 2005, 658 patients were treated with
SES (87% male, mean age 63  9) und 294 patients with BMS
(79%male, mean age 64  10). After 18 months, 13% of the SES
cohort and 20% of the BMS cohort had suffered a MACE (p
adjusted < 0.01). Initial hospital costs were signiﬁcantly higher
for SES than for BMS (6001  57 vs. 3913  69 EUR, p
adjusted < 0.01) and the respective 18-month follow-up direct
and indirect costs were similar (7949  462 vs. 8360  554 EUR
p adjusted = 0.455). Over 18 months, total TVR-related and
disease-related costs were higher in SES compared to BMS:
12,876  438 vs. 11,501  525 EUR and 13,950  468 vs.
12,273  562 EUR, respectively, both p adjusted < 0,01. For
TVR costs, the cost-effectiveness of SES was 15,995 EUR per
patient free from MACE and for total disease-related costs,
19,500 EUR. CONCLUSION: In comparison to patients follow-
ing BMS implantation, patients 18 months following implanta-
tion of SES experienced signiﬁcantly fewer MACE. The higher
initial costs for SES compare to BMS were followed by similar
economic consequences in both groups with cost-effectiveness of
under 20,000 EUR per patient free from MACE.
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OBJECTIVES: To evaluate the cost-effectiveness of serolimus-
eluting stents (SES) to bare-metal stents (BMS) in patients with
single-vessel coronary artery disease (SVD) compared with
patients with multi-vessel disease (MVD). METHODS: In the
prospective GERSHWIN study in 35 hospitals in Germany,
patients with coronary artery disease (CAD) undergoing percu-
taneous coronary intervention (PCI) were electively treated with
SES or BMS (sequential control design). Standardized question-
naires completed by patients and physicians through 18 months
following PCI documented major adverse coronary events
(MACE), including death, myocardial infarction, coronary artery
bypass surgery and re-PCI in target vessel, as well as disease-
related direct and indirect costs. RESULTS: From April 2003
until June 2005, 658 patients were treated with SES (87% male,
mean age 63  9) und 294 patients with BMS (79% male, mean
age 64  10). SVD was documented in 34% BMS patients and
29% SES patients. After 18 months, 8% of SES and 25% of BMS
patients with SVD had suffered MACE in comparison to 15% of
SES and 19% of BMS patients with MVD, indicating a difference
in the effect of SES with respect to the underlying CAD status (p
adjusted = 0.023). In SVD, SES and BMS incurred total costs of
EUR 11,832 and 12,399, respectively. In MVD, SES and BMS
incurred total costs of EUR 14,964 and 12,026, respectively (p
adjusted = 0.003). In patients with SVD, the cost-effectiveness of
SES was EUR 12,805 per patient free from MACE compared to
EUR 16,488 in BMS. In patients with MVD, the cost-
effectiveness of SES was EUR 17,522 per patient free from
MACE compared to EUR 14,810 in BMS. CONCLUSION: In
patients with SVD, SES is more cost effective than BMS whereas
in patients with MVD, SES is less cost effective than BMS.
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OBJECTIVES: The purpose of this study was to evaluate the
relative cost-effectiveness (cost-utility) of the angiotensin II
antagonist eprosartan versus other antihypertensives (nitren-
dipine, perindopril, enalapril) in a secondary prevention setting
(hypertensives with cerebrovascular disease at baseline) in
Belgium, Germany, Spain, UK and Sweden. METHODS: The
HEALTH model (Health Economic Assessment of Life with
Teveten® for Hypertension) is an object-oriented probabilistic
Monte Carlo simulation model. It combines a Framingham-
based risk calculation with a systolic blood pressure approach to
estimate the relative risk reduction of cardiovascular and cere-
brovascular events based on recent meta-analyses. For eprosar-
tan an additional risk reduction was modelled according to the
results of the MOSES study (‘Morbidity and Mortality after
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Stroke—Eprosartan Compared to Nitrendipine for Secondary
Prevention’). Costs and utilities were derived from published
estimates considering country-speciﬁc health care payer perspec-
tives. Drug prices of the comparators were based on the cheapest
generics. The treatment time horizon simulated was 2.5 years
(mean observation period of the MOSES study) modelling
follow-up effects over a life-time. Costs and effects were dis-
counted according to country-speciﬁc guidelines. RESULTS:
During a 2.5-year treatment time horizon modelling follow-up
effects over lifetime in 1,000 patients eprosartan treatment
avoided about 58 events (26 cardiovascular, 32 cerebrovascular)
and produced about 30 incremental QALYs versus the compared
treatments. Irrespective of country and comparator the cost per
QALY gained by eprosartan never exceeded €20,000 and there-
fore went far below the estimated willingness-to-pay threshold of
€30,000. The probabilistic sensitivity analyses fortify these out-
comes by showing a probability of 90–100% that eprosartan is a
cost-effective treatment strategy. CONCLUSION: Even compar-
ing eprosartan to low-priced generic substances, the HEALTH
model simulations provide evidence that eprosartan treatment is
associated with obvious health beneﬁts being obtained at reason-
able cost. Eprosartan should therefore be considered a good
treatment option for hypertensive patients with cerebrovascular
disease.
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OBJECTIVES: To examine in randomized controlled trial the
effectiveness and cost-effectiveness of arthroscopic acromioplasty
in the treatment of stage II shoulder impingement syndrome.
METHODS: We divided 140 patients into supervised exercise
program (n = 70, exercise group) and arthroscopic acromio-
plasty, followed by a similar exercise program (n = 70, combined
treatment group). The primary health outcome measure was
self-reported pain on a 0–10 Visual Analogue Scale at 24 months
with a two-point change deﬁned as minimal clinically important
difference (MCID). RESULTS: Results In an intention-to-treat
analysis an improvement exceeding MCID took place from base-
line to 24 months in both groups: self-reported pain diminished
from 6.5 to 2.9 in the exercise group (N = 66) and from 6.4 to
2.5 in the combined treatment group (n = 68) (P < 0.001 in
both). In the combined treatment group pain relief was attained
faster, but the groups did not any more differ at 24 months
(P = 0.37). A similar pattern was seen in the secondary outcome
measures: disability, pain at night, SDQ score, ability to work,
number of painful days and proportion of pain-free patients. The
mean total cost was €2961 in the combined treatment group and
€1864 in the exercise group. The incremental cost-effectiveness
ratio was €5852 per MCID unit, i.e., combined treatment was
considerably more costly. CONCLUSION: Arthroscopic acro-
mioplasty does not provide any signiﬁcant additional value over
structured and supervised exercise program alone in terms of
subjective outcome or cost-effectiveness. Operative treatment
should be offered judiciously.
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OBJECTIVES: For patients with renal failure who from amedical
perspective can be treated with either haemodialysis (HD) or
peritoneal dialysis (PD), the choice of treatment ismainly based on
administrative, economic and patient preference considerations.
HD is performed 3–5 times per week in a hospital, while PD is
performed daily at home. Both are ﬁnanced over hospitals’
budgets inNorway. This evaluation compared the costs ofHDand
PD from both a societal and a hospital perspective for such
patients. METHODS: Costs were calculated based on national
data on resource use and unit costs. Estimates of resource use were
based on treatment guidelines, the literature and interviews at
three major hospitals in Norway. Unit costs were based on tariffs,
price lists, hospital accounts and salary statistics. In the societal
perspective, costs were divided in three sections: Costs born by
patients (co-payments, transportation and value of time), costs
born by hospitals (personnel, medicines and supplies, laboratory
tests, capital and infrastructure) and other public costs (funding of
medicines). In the hospital perspective, net cost was calculated
(difference between expenses and income). RESULTS: From a
societal perspective the averagemonthly cost per patient is for PD:
30,700NOK (~3,800€) and for HD: 51,800NOK (~6,400€). The
main cost driver for PD is dialysis solutions: 23,800 NOK
(~2,900€). The cost components in HD are more homogeneous.
Hospitals go about break-even performing PDand have amonthly
net income of about 600 NOK (~75€) when performing HD.
CONCLUSION: For patients who can use either treatment
modality, PD is a cost saving alternative to HD from a societal
perspective. However, the ﬁnancing systems for dialysis in
Norway make hospitals relatively neutral from an economical
perspective in their choice of HD or PD for these patients.
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OBJECTIVES: Globally there is considerable variation in public
funding for IVF treatments. IVF is unique amongst health inter-
ventions because its success leads to human life. In light of this
uniqueness we apply a Generational Accounting approach, an
accepted method used by tax authorities, to assess whether pub-
licly funded IVF represents sound ﬁscal policy. Our assessment
considers future lifetime net tax contributions to the British
government (taxes paid minus transfer payments) attributed to a
successful IVF birth. METHODS: Net present value (NPV) cal-
culations were applied to the average cost per successful IVF
conceived live birth (£12,931 in 2005), lifetime direct cash trans-
fers and lifetime future tax contributions discounted using estab-
lished Treasury department rates. We assume the following:
full-time education aged 6–19; full-time employment aged 20–68
(Pension Commission, 2005); education costs, child-tax credits,
and pension contributions increase with inﬂation. Age-speciﬁc
income was adjusted for inﬂation over time, and we allowed
expected income to vary with age. Current government tax rev-
enues of 35.5% gross income were held constant. RESULTS:
Based on average life-expectancy the model indicates an
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